Reducing the growing burden of cardiovascular disease in the developing world

Health Affairs

Volumn 26, Issue 1, 2007, Pages 13-24

  Gaziano, Thomas A ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGE DISTRIBUTION; AGED; CARDIOVASCULAR DISEASE; COST OF ILLNESS; DEVELOPING COUNTRY; ECONOMICS; FEMALE; HEALTH; HOSPITALIZATION; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; INCIDENCE; LIFESTYLE; MALE; METHODOLOGY; MIDDLE AGED; OBESITY; PRIMARY PREVENTION; REVIEW; RISK ASSESSMENT; RISK FACTOR; SEX RATIO; SMOKING; UNITED STATES;

AGE DISTRIBUTION; AGED; AGED, 80 AND OVER; CARDIOVASCULAR DISEASES; COST OF ILLNESS; DEVELOPING COUNTRIES; FEMALE; HUMANS; HYPERLIPIDEMIAS; HYPERTENSION; INCIDENCE; LIFE STYLE; MALE; MIDDLE AGED; OBESITY; PRIMARY PREVENTION; RISK ASSESSMENT; RISK FACTORS; SEVERITY OF ILLNESS INDEX; SEX DISTRIBUTION; SMOKING; UNITED STATES; WORLD HEALTH;

EID: 33846661712     PISSN: 02782715     EISSN: 02782715     Source Type: Journal    
DOI: 10.1377/hlthaff.26.1.13     Document Type: Review

References (47)

1. T.A. Gaziano, "Cardiovascular Disease in the Developing World and Its Cost-Effective Management," Circulation 112, no. 23 (2005): 3547-3553.
2. A.D. Lopez et al., eds., Global Burden of Disease and Risk Factors (Washington: Oxford University Press and World Bank, 2006).
3. T. Thom et al., "Heart Disease and Stroke Statistics - 2006 Update: A Report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee," Circulation 113, no. 6 (2006): e85-e151.
4. D. Jamison et al., eds., Disease Control Priorities in Developing Countries, 2d ed. (New York: Oxford University Press and World Bank, 2006).
5. C.D. Mathers et al., "Deaths and Disease Burden by Cause: Global Burden of Disease Estimates for 2001 by World Bank Country Groups," Disease Control Priorities Project Working Paper no. 18 (Bethesda, Md.: Fogarty International Center, National Institutes of Health, 2001).
6. T.A. Gaziano et al., "Cardiovascular Disease," in Disease Control Priorities, ed. Jamison et al., 645-662.
7. A.R. Omran, "The Epidemiologic Transition: A Theory of the Epidemiology of Population Change," Milbank Quarterly 49, no. 4 (1971): 509-538;
8. and S.J. Olshansky and A.B. Ault, "The Fourth Stage of the Epidemiologic Transition: The Age of Delayed Degenerative Diseases," Milbank Quarterly 64, no. 3 (1986): 355-391.
9. S. Yusuf et al., "Global Burden of Cardiovascular Diseases, Part I: General Considerations, the Epidemiologic Transition, Risk Factors, and Impact of Urbanization," Circulation 104, no. 22 (2001): 2746-2753.
10. S. Leeder et al., A Race against Time: The Challenge of Cardiovascular Disease in Developing Countries (New York: Trustees of Columbia University, 2004).
11. E. Bertrand, Cardiovascular Disease in Developing Countries (New York: McGraw-Hill, 1999).
12. J.A. Pestana et al., "The Direct and Indirect Costs of Cardiovascular Disease in South Africa in 1991," South African Medical Journal 86, no. 6 (1996): 679-684.
13. Leeder et al., A Race against Time.
14. World Bank, World Development Indicators (Washington: World Bank, 2002).
15. American Heart Association, Heart Disease and Stroke Statistics - 2004 Update (Dallas: AHA 2003); and Pestana et al., "The Direct and Indirect Costs."
16. World Health Organization, Macroeconomics and Health: Investing in Health for Economic Development - Report of the Commission on Macroeconomics and Health (Geneva: WHO, 2001).
17. R. Laxminarayan et al., "Advancement of Global Health: Key Messages from the Disease Control Priorities Project," Lancet 367, no. 9517 (2006): 1193-1208.
18. J. Kupersmith et al., "Cost-Effectiveness Analysis in Heart Disease, Part II: Preventive Therapies," Progress in Cardiovascular Disease 37, no. 4 (1995): 243-271.
19. P. Puska et al., "The North Karelia Project: Fifteen Years of Community-Based Prevention of Coronary Heart Disease," Annals of Medicine 21, no. 3 (1989): 169-173.
20. W. Willet et al., "Prevention of Chronic Disease by Diet and Lifestyle Changes," in Disease Control Priorities, ed. Jamison et al., 833-850.
21. P. Jha et al., "Tobacco Addiction," in Disease Control Priorities, ed. Jamison et al., 869-886.
22. Ibid.
23. R. Peto et al., "Smoking, Smoking Cessation, and Lung Cancer in the U.K. since 1950: Combination of National Statistics with Two Case-Control Studies," British Medical Journal 321, no. 7257 (2000): 323-329;
24. and P. Jha et al., "Estimates of Global and Regional Smoking Prevalence in 1995, by Age and Sex," American Journal of Public Health 92, no. 6 (2002): 1002-1006.
25. Jha et al., "Tobacco Addiction."
26. F.J. Chaloupka et al., eds., The Taxation of Tobacco Products (Oxford: Oxford University Press, 2000).
27. Centers for Disease Control and Prevention, "Medical-Care Expenditures Attributable to Cigarette Smoking - United States, 1993," Morbidity and Mortality Weekly Report 43, no. 26 (1994): 469-472.
28. Jha et al., "Tobacco Addiction."
29. Ibid.
30. A. Rodgers et al., "The Growing Burden of Risk from High Blood Pressure, Cholesterol, and Bodyweight," in Disease Control Priorities, ed. Jamison et al., 851-868.
31. R. Jackson et al., "Treatment with Drugs to Lower Blood Pressure and Blood Cholesterol Based on an Individual's Absolute Cardiovascular Risk," Lancet 365, no. 9457 (2005): 434-441;
32. and B. Williams et al., "Guidelines for Management of Hypertension: Report of the Fourth Working Party of the British Hypertension Society, 2004-BHS IV," Journal of Human Hypertension 18, no. 3 (2004): 139-185.
33. T.A. Gaziano et al., "Cost-Effectiveness Analysis of Hypertension Guidelines in South Africa: Absolute Risk versus Blood Pressure Level," Circulation 112, no. 23 (2005): 3569-3576.
34. R.M. Batussen et al., Generalized Cost-Effectiveness Analysis: A Guide (Geneva: WHO, 2002).
35. Ibid.; and N.J. Wald and M.R. Law, "A Strategy to Reduce Cardiovascular Disease by More than 80 Percent," British Medical Journal 326, no. 7404 (2003): 1419.
36. B. Carlberg, O. Samuelsson, and L.H. Lindholm, "Atenolol in Hypertension: Is It a Wise Choice?" Lancet 364, no. 9446 (2004): 1684-1689;
37. L.H. Lindholm, B. Carlberg, and O. Samuelsson, "Should Beta Blockers Remain First Choice in the Treatment of Primary Hypertension? A Meta-Analysis," Lancet 366, no. 9496 (2005): 1545-1553;
38. and L.H. Opie and R. Schall, "Old Antihypertensives and New Diabetes," Journal of Hypertension 22, no. 8 (2004): 1453-1458.
39. T.A. Gaziano, L.H. Opie, and M.C. Weinstein, "Cardiovascular Disease Prevention with a Multidrug Regimen in the Developing World: A Cost-Effectiveness Analysis," Lancet 368, no. 9536 (2006): 679-686.
40. Ibid.
41. Jamison et al., eds., Disease Control Priorities.
42. J.J. McMurray and S. Stewart, "Epidemiology, Aetiology, and Prognosis of Heart Failure," Heart 83, no. 5 (2000): 596-602.
43. M.R. Law, H.C. Watt, and N.J. Wald, "The Underlying Risk of Death after Myocardial Infarction in the Absence of Treatment," Archives of Internal Medicine 162, no. 21 (2002): 2405-2410.
44. Gaziano et al., "Cardiovascular Disease."
45. S. Mendis et al., "WHO Study on Prevevention of Recurrences of Myocardial Infarction and Stroke (WHO-PREMISE)," Bulletin of the World Health Organization 83, no. 11 (2005): 820-829.
46. Gaziano et al., "Cardiovascular Disease Prevention."
47. R. Beaglehole et al., World Health Report 2003: Shaping the Future (Geneva: WHO, 2003).